Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 940 | 16.43 |
09:39 ET | 360 | 16.36 |
09:48 ET | 200 | 16.175 |
09:50 ET | 100 | 16.075 |
09:52 ET | 200 | 16.0025 |
09:54 ET | 100 | 16.0025 |
09:56 ET | 400 | 16.055 |
09:57 ET | 700 | 16.02 |
09:59 ET | 1900 | 16.135 |
10:01 ET | 100 | 16.135 |
10:03 ET | 208 | 16.095 |
10:06 ET | 1321 | 16.1 |
10:08 ET | 600 | 16.095 |
10:10 ET | 100 | 16.095 |
10:12 ET | 1039 | 16.155 |
10:14 ET | 568 | 16.19 |
10:17 ET | 600 | 16.2 |
10:19 ET | 361 | 16.2 |
10:21 ET | 200 | 16.205 |
10:24 ET | 700 | 16.24 |
10:26 ET | 100 | 16.22 |
10:30 ET | 600 | 16.21 |
10:32 ET | 513 | 16.235 |
10:33 ET | 200 | 16.21 |
10:35 ET | 692 | 16.23 |
10:37 ET | 200 | 16.27 |
10:44 ET | 429 | 16.28 |
10:48 ET | 742 | 16.25 |
10:50 ET | 200 | 16.25 |
10:51 ET | 1899 | 16.24 |
10:55 ET | 500 | 16.245 |
10:57 ET | 200 | 16.245 |
11:00 ET | 100 | 16.245 |
11:02 ET | 2397 | 16.19 |
11:04 ET | 100 | 16.19 |
11:06 ET | 100 | 16.185 |
11:08 ET | 200 | 16.18 |
11:09 ET | 435 | 16.175 |
11:11 ET | 650 | 16.21 |
11:13 ET | 100 | 16.185 |
11:15 ET | 332 | 16.185 |
11:18 ET | 1000 | 16.14 |
11:20 ET | 400 | 16.165 |
11:26 ET | 500 | 16.17 |
11:27 ET | 400 | 16.18 |
11:31 ET | 1000 | 16.145 |
11:33 ET | 200 | 16.15 |
11:36 ET | 726 | 16.135 |
11:38 ET | 100 | 16.14 |
11:40 ET | 1704 | 16.13 |
11:42 ET | 100 | 16.135 |
11:44 ET | 2235 | 16.135 |
11:49 ET | 421 | 16.135 |
11:51 ET | 1558 | 16.16 |
11:54 ET | 200 | 16.15 |
11:56 ET | 400 | 16.2 |
11:58 ET | 745 | 16.21 |
12:02 ET | 400 | 16.24 |
12:07 ET | 1300 | 16.3 |
12:09 ET | 319 | 16.318 |
12:20 ET | 2323 | 16.24 |
12:21 ET | 124 | 16.235 |
12:27 ET | 512 | 16.23 |
12:36 ET | 100 | 16.29 |
12:38 ET | 100 | 16.315 |
12:39 ET | 300 | 16.29 |
12:45 ET | 200 | 16.265 |
12:48 ET | 350 | 16.25 |
12:50 ET | 600 | 16.245 |
12:54 ET | 100 | 16.24 |
12:59 ET | 400 | 16.27 |
01:01 ET | 100 | 16.25 |
01:06 ET | 1470 | 16.248 |
01:08 ET | 200 | 16.25 |
01:10 ET | 100 | 16.26 |
01:19 ET | 400 | 16.25 |
01:26 ET | 317 | 16.25 |
01:30 ET | 100 | 16.25 |
01:32 ET | 500 | 16.25 |
01:33 ET | 900 | 16.245 |
01:35 ET | 2771 | 16.16 |
01:39 ET | 561 | 16.135 |
01:46 ET | 600 | 16.19 |
01:48 ET | 100 | 16.17 |
01:51 ET | 200 | 16.17 |
01:53 ET | 481 | 16.17 |
01:55 ET | 100 | 16.17 |
01:57 ET | 300 | 16.16 |
02:02 ET | 100 | 16.17 |
02:06 ET | 1843 | 16.25 |
02:08 ET | 200 | 16.25 |
02:15 ET | 100 | 16.27 |
02:18 ET | 650 | 16.3 |
02:22 ET | 497 | 16.34 |
02:33 ET | 1816 | 16.25 |
02:36 ET | 230 | 16.25 |
02:42 ET | 100 | 16.23 |
02:44 ET | 219 | 16.25 |
02:51 ET | 500 | 16.26 |
02:54 ET | 100 | 16.24 |
02:56 ET | 100 | 16.25 |
02:58 ET | 620 | 16.25 |
03:00 ET | 101 | 16.25 |
03:02 ET | 600 | 16.225 |
03:03 ET | 810 | 16.21 |
03:05 ET | 200 | 16.205 |
03:09 ET | 800 | 16.215 |
03:12 ET | 100 | 16.215 |
03:14 ET | 440 | 16.21 |
03:16 ET | 300 | 16.23 |
03:18 ET | 1350 | 16.185 |
03:20 ET | 2597 | 16.175 |
03:23 ET | 500 | 16.18 |
03:25 ET | 811 | 16.2 |
03:27 ET | 500 | 16.215 |
03:30 ET | 400 | 16.205 |
03:32 ET | 1128 | 16.215 |
03:34 ET | 1790 | 16.21 |
03:36 ET | 3096 | 16.26 |
03:38 ET | 827 | 16.23 |
03:39 ET | 1376 | 16.235 |
03:41 ET | 500 | 16.24 |
03:43 ET | 810 | 16.26 |
03:45 ET | 1000 | 16.25 |
03:48 ET | 300 | 16.25 |
03:50 ET | 3089 | 16.195 |
03:52 ET | 9575 | 16.38 |
03:54 ET | 7266 | 16.4 |
03:56 ET | 10504 | 16.395 |
03:57 ET | 6024 | 16.33 |
03:59 ET | 5789 | 16.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 575.0M | -5.9x | --- |
Humacyte Inc | 571.6M | -4.8x | --- |
Mineralys Therapeutics Inc | 580.9M | -5.4x | --- |
Erasca Inc | 561.6M | -2.8x | --- |
Cassava Sciences Inc | 592.5M | -10.6x | --- |
Savara Inc | 556.9M | -10.5x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $575.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-2.79 |
Book Value | $5.48 |
P/E Ratio | -5.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.